Vertex Pharmaceuticals
NEWS
Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
Cystic fibrosis drugmaker Vertex was forced to destroy nearly 8,000 packs of its drug Orkambi after the medication had expired before they could be shipped to the United Kingdom due to a contentious pricing fight.
This morning, Boston-based Vertex said its triple-combination treatment VX-445, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function in two late-stage cystic fibrosis trials.
With Boston and the surrounding area being one of the centers of the pharmaceutical world, it should come as no surprise that some of the top-selling medications are based in the Bay State.
Movers and Shakers is BioSpace’s weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
Vertex fired Chief Operating Officer Ian Smith, who had also been serving as interim chief financial officer since December. The Boston-based company said it promptly launched a comprehensive investigation into the allegations made against Smith with the assistance of an independent external counsel.
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
The Orphan Drug Act (ODA) was enacted on January 4, 1983. It was designed to encourage the development of drugs for rare diseases. The law was amended the following year to define rare diseases as ones that affect fewer than 200,000 people in the U.S. But it also included drugs that affect more than 200,000 people the costs of developing and marketing the drug in the U.S. would exceed revenue from U.S. sales.
With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.
JOBS
IN THE PRESS